SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, as traders debate whether AI spending and profitability concerns signal a deeper sector correction; supply-chain worries and broader market risk also weigh on sentiment. The community is split between buying an oversold dip in hopes of a rebound and expecting further losses, with many noting that the funds 3 leverage amplifies volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

An early leak of Moderna and Mercks Phase 3 melanoma-vaccine results sparked a sharp selloff, despite the combination reducing recurrence or death risk versus Keytruda alone. Traders are split between viewing the results as positive clinical progress and seeing them as short of expectations after a major run-up, with debate over valuation and prospects for the vaccine.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong quarterly results and raised full-year outlook were followed by a sharp selloff, with traders focused on negative cash flow and heavy investment in capacity amid a high valuation and broader weakness in AI-related stocks. Bulls view the spending as growth investment backed by data-center power demand, while bears question cash generation and whether expectations had become too high.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

CRDO is drawing attention after a steep selloff amid weakness across AI and semiconductor stocks, with traders noting no clear company-specific trigger. The debate centers on valuation and recurring insider sales versus dip-buyers who believe demand for AI data-center connectivity remains strong.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPEs sharp price rebound is driving attention, with traders celebrating the move and speculating it could gain ground on SHIB. The discussion is largely momentum-focused, while some traders question whether the rally can hold amid low-volume concerns and broader crypto-market swings.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly update is driving attention: earnings beat expectations, but revenue missed and management lowered its sales outlook as shoppers became more price-conscious and footwear promotions increased; higher earnings guidance was partly supported by tariff refunds. Traders are debating the sharp selloff despite the earnings beat, with bulls citing strong margins and buybacks while bears focus on slower growth and weaker demand.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

RYCEY is drawing attention after a sharp pullback from its recent highs, with traders debating whether the decline reflects profit-taking and broader market rotation or concerns about higher oil and jet-fuel costs and Middle East disruption to aviation. Many holders argue the companys fundamentals and buybacks remain intact, while others question the persistent selling and valuation.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is trending on its Q3 earnings: adjusted earnings beat expectations, while revenue came in slightly below forecasts; card spending grew and credit-loss provisions declined. Traders are largely emphasizing the strong earnings and outlook, though some note the revenue miss and distinguish the reported guidance from the adjusted outlook.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a tech-led selloff, as traders question whether heavy AI investment will generate sufficient returns; rising oil prices and Iran-related tensions are adding inflation and risk concerns. The community is divided between expectations of further declines and dip-buying or a short-term rebound.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong earnings and upbeat outlook have been met with a sharp selloff, prompting traders to question why positive results failed to lift the shares. The debate centers on higher capital spending, potential supply growth and peak-cycle concerns, alongside broader weakness in AI- and storage-related stocks; bullish traders point to resilient data-storage demand and pricing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precigens commercial launch of PAPZIMEOS and its strong sales momentum are driving attention, alongside expectations for PRGN-2009 cancer-trial data and a possible European decision. Traders are bullish on the growth and short-squeeze potential, while others debate competition from INOVIOs pending FDA decision and the risk of volatility.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.

The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies 

Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>B. Riley initiated coverage of PGEN with a ‘Buy’ rating and $12 target, implying more than 50% upside.</li><li><a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a> touched a fresh 52-week high as Bernstein highlighted Intismeran as the clearest validation yet of Moderna’s broader <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">mRNA</a> platform.</li><li>Moderna is headed toward detailed Phase 3 melanoma data at ESMO in October, while Precigen is ramping up the commercial launch of Papzimeos.</li></ul>Moderna (<a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a>) and Precigen (PGEN) hit new milestones on Friday, as investors weighed fresh Wall Street commentary on the biotech companies’ cancer-focused therapies.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> gained 1.5% to their highest level since January 2023, while <a href="https://stocktwits.com/symbol/PGEN">PGEN shares</a> edged marginally lower after hitting over five-year highs.<h2 class="st-heading-2">B Riley Sees Papzimeos Traction</h2>Precigen received a bullish Wall Street call on Friday, with B. Riley initiating coverage with a ‘Buy’ rating and a $12 price target. This represents more than 50% upside from current levels.The brokerage highlighted the early commercial performance of Papzimeos, Precigen’s lead therapy and the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), a rare disease that causes tumors to repeatedly grow in the respiratory tract.The FDA recently approved Papzimeos, marking Precigen’s transition into a commercial-stage company. B. Riley noted that the approval did not require a confirmatory trial, removing a potential additional development burden for the company.The brokerage said Papzimeos’ launch is progressing faster than several recent rare-oncology drug launches.<h2 class="st-heading-2">Bernstein’s Take On <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a>’s Intismeran</h2>Moderna remained in focus on Friday after Bernstein reiterated a ‘Market Perform’ rating. The firm highlighted Intismeran, Moderna’s personalized cancer therapy developed with Merck (MRK), as the strongest validation yet of the company’s <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">mRNA</a> platform beyond vaccines. Moderna recently reported positive Phase 3 results in high-risk melanoma, with the study meeting both of its main goals at an interim analysis.Moderna is expected to present detailed results at the ESMO Congress in October. The company is also testing Intismeran across several other cancers and treatment settings as it looks to broaden the therapy’s potential.At Bernstein’s healthcare conference this week, CEO Stéphane Bancel stressed the breadth of Moderna’s pipeline, saying Intismeran is “not our best product,” despite its promising results.<h2 class="st-heading-2">How Have PGEN And <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a> Performed This Year?</h2>Retail sentiment surrounding <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a> turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, while sentiment for PGEN remained ‘bullish.’While PGEN shares have recorded a solid 80% gain this year, <a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">MRNA</a> stock has surged more than 540% due to the trial success of Intismeran.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/fslr-stock-heads-for-its-worst-week-in-over-month-roth-us-polysilicon/cZMOL6zRBO0">FSLR Stock Heads For Its Worst Week In Over A Month — Roth Says US Polysilicon Crackdown Could Provide A Tailwind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

 Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$6.39
Prev Close	$6.60
Open	$6.50
Dividend Yield	0.00%
50-Day Moving Average	$7.27
Beta	1.75
Avg. Volume	4.67M
PE Ratio	-5.81

52-Week High	$8.98
52-Week Low	$3.04
Market Capitalization	$2.29B
EPS (Annual)	-$1.37
Price to Book	52.50
Revenue Per Employee	$60,525.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PGEN Fundamentals